Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE INCLUSION OF VELSIPITY® AND XERAVA® IN CHINA'S 2026 NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that VELSIPITY® (etrasimod arginine tablets) and XERAVA® (eravacycline hydrochloride for injection) have been included in the 2026 National Reimbursement Drug List (the "**NRDL**") for the first time. This inclusion will further improve the accessibility and affordability of VELSIPITY® and XERAVA®, enabling more patients to benefit from innovative treatments. The updated NRDL will take effect on 1 January 2027. In addition, NEFECON® (budesonide delayed-release capsules) will continue to be included in the updated NRDL.

VELSIPITY® (etrasimod arginine tablets) is China's first and only (as of November 2026) selective sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of ulcerative colitis ("**UC**"). The inclusion of VELSIPITY® in the NRDL expands access to an innovative, once-daily oral treatment for UC that is recommended by clinical guidelines as a first-line therapy. XERAVA® (eravacycline) is the world's first and only (as of November 2026) fully synthetic fluorocycline antibiotic. It is indicated for the treatment of complicated intra-abdominal infections ("**cIAI**") in adults and is characterized by a broad antimicrobial spectrum, potent antibacterial activity, confirmed clinical efficacy, and a favorable safety profile.

About VELSIPITY® (etrasimod arginine tablets)

VELSIPITY® (etrasimod arginine tablets) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4 and 5. National Medical Products Administration (NMPA) of China has approved VELSIPITY® in February 2026, for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Results from the ENLIGHT UC study (ES101002) demonstrated that the clinical remission rate after 12-week induction period followed by 40-week maintenance period reached 48.1%, and the mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%. As the largest Phase 3 registrational study in Asian patients with moderately to severely active UC, the study confirmed the efficacy and safety of VELSIPITY® with results published in The Lancet Gastroenterology & Hepatology. Results from the ELEVATE UC open-label extension demonstrated that continuous treatment with VELSIPITY® for up to 3 years resulted in 86.8% patients achieving clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%. Safety data extending up to five years from the global clinical study further confirm that VELSIPITY® is well tolerated and maintains a favorable and stable safety profile.

Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in 2024 as a first-line treatment for ulcerative colitis, VELSIPITY® was also included in the American College of Gastroenterology (ACG) Clinical Guideline updated in 2025, with strong recommendation supporting its use for both induction and maintenance treatment in patients with moderately to severely active UC.

Regulatory approvals have been granted in the United States of America, European Union, Canada, Japan, Australia, United Kingdom, Switzerland, Israel, Turkey, India, United Arab Emirates, Qatar, Republic of Ecuador, Mexico, Macau SAR, Singapore, Hong Kong SAR, the Chinese Mainland, South Korea, Taiwan region, China for VELSIPITY® in the treatment of UC.

About XERAVA® (eravacycline hydrochloride for injection)

XERAVA® (eravacycline hydrochloride for injection), is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment infections caused by susceptible Gram-positive, Gram-negative and anaerobic pathogens including those multidrug resistant (MDR) isolates.

XERAVA® has been recommended in The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection and in multiple global treatment guidelines issued by Infectious Disease Society of America's (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as a treatment choice for multi-drug resistant Gram-negative bacterial infections including Carbapenem resistant organisms. In addition, it was included in an expert consensus on the multi-disciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, Infectious Diseases Society for Evidence-based and Translational Medicine of Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery.

XERAVA® is currently approved for the treatment of cIAI in the United States of America, European Union, United Kingdom, Singapore, the Chinese Mainland and Hong Kong SAR. In March 2023, National Medical Products Administration (NMPA) of China approved New Drug Application (NDA) for XERAVA® for the treatment of cIAI in adult patients. The Company launched XERAVA® in July 2023 in the Chinese Mainland.

By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 16 November 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.